ArticleFrontiers in cardiovascular medicine2026
The CALLY index as a novel predictor of left ventricular aneurysm in patients with ST-segment elevation myocardial infarction.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Left ventricular aneurysm (LVA) is a serious mechanical complication following ST-segment elevation myocardial infarction (STEMI). The C-reactive protein-albumin-lymphocyte index (CALLY) is a novel composite inflammatory biomarker, but its predictive value for LVA remains unclear. Methods: We retrospectively enrolled 1,507 STEMI patients who underwent primary percutaneous coronary intervention (pPCI) between January 2020 and March 2026. Patients were divided into quartiles based on CALLY levels. Restricted cubic spline (RCS) analysis was used to explore the dose-response relationship. Least absolute shrinkage and selection operator (LASSO) regression was used for variable screening. Multivariable logistic regression was performed to identify independent predictors. A nomogram was built and validated using receiver operating characteristic (ROC) curves, bootstrap calibration curves, and decision curve analysis (DCA). Results: LVA occurred in 157 patients (10.42%). The incidence of LVA declined gradually with increasing CALLY quartiles (27.32%, 7.18%, 3.98%, 3.18%; Conclusion: A lower admission CALLY index was independently associated with a higher risk of LVA in STEMI patients treated with pPCI. The CALLY-based nomogram supports reliable risk stratification and may assist with early clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.